Results 41 to 50 of about 37,267 (288)

Review Article of Cardiac Amyloidosis

Walailak Journal of Science and Technology, 2011
Cardiac amyloidosis is a term that means the deposit of abnormal proteins in the myocardium leading to global thickening of the heart walls. The clinical character is that of infiltrative cardiomyopathy.
Jittiporn PURATTANAMAL
doaj   +1 more source

Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs

Hemato, 2022
The survivorship needs of patients with light-chain (AL) amyloidosis are complex, as is the diagnosis and treatment itself. Early diagnosis is critical in improving patient outcomes; however, given the nonspecific nature of the symptoms, most patients ...
Hamza Hassan, Vaishali Sanchorawala
doaj   +1 more source

Upfront CyBorD in AL amyloidosis [PDF]

Blood, 2015
In this issue of Blood , [Palladini et al][1] report on the outcome of a large series of 230 patients with systemic immunoglobulin (Ig) amyloid light chain (AL) amyloidosis treated frontline with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) at 2 referral centers.[1][2] ![Figure][3]
M. Teresa Cibeira, Joan Bladé
openaire   +3 more sources

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Recurrent syncope and cardiac arrest in a patient with systemic light chain amyloidosis treated with bortezomib

Hematology Reports, 2016
About 10-15% of patients with multiple myeloma develop light chain (AL) amyloidosis. AL amyloidosis is a systemic disease that may involve multiple organs, often including the heart. It may present clinically with bradyarrhythmia and syncope.
Navin Jaipaul, Alexander Pi, Zhiwei Zhang   +2 more
doaj   +1 more source

Localized AL amyloidosis

Terapevticheskii arkhiv
Localized light chain (AL) amyloidosis (amyloidoma) is a rare disease with unclear pathogenesis and undeveloped approaches to therapy. This article presents 3 clinical observations of localized AL amyloidosis with lesions of the respiratory tract, eyes, and soft tissues of the face.
Nelly A. Kashchavtseva, Irina G. Rekhtina, Alla M. Kovrigina, Tatyana P. Danilina, Larisa P. Mendeleeva   +4 more
openaire   +3 more sources

Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy

Advanced Healthcare Materials, EarlyView.
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq, Punnya Anil Kumar Jeeja, Sudip Kumar Dam, Sabya Sachi Das, Juan L. Vivero‐Escoto   +4 more
wiley   +1 more source

Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021

Diagnostics, 2021
Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease.
Weijia Li, Dipan Uppal, Yu Chiang Wang, Xiaobo Xu, Damianos G. Kokkinidis, Mark I. Travin, James M. Tauras   +6 more
doaj   +1 more source

Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision

Advanced Healthcare Materials, EarlyView.
Advancements in ART improve HIV‐1 patient outcomes but are unable to eliminate latent viral DNA. To address this, CXCR4‐targeted lipid nanoparticles (T‐LNPs) for delivering CRISPR‐Cas9 to excise HIV‐1 DNA in infected cells are developed. These T‐LNPs achieve ≈60% HIV‐1 DNA excision efficacy in blood and splenic tissue, demonstrating promise for ...
Sudipta Panja, Lubaba A. Zaman, Chen Zhang, Milankumar Patel, Santhi Gorantla, Prasanta K. Dash, Howard E. Gendelman   +6 more
wiley   +1 more source

Kidney-limited AL amyloidosis: a case report and review of the literature

Journal of Community Hospital Internal Medicine Perspectives, 2021
Amyloidosis involves the deposition of abnormal proteins in various tissues and results in progressive organ dysfunction, commonly affecting multiple organs.
Sara Velayati, Alexander Belkin, Gurwinder Sidhu Kumar, Zubin J Tharayil, Neeru Kumar, Samir Patel   +5 more
doaj   +1 more source